Pancreatic cancer pill daraxonrasib halts tumours in most patients, trial shows

RUKUS· · 13h ← 2d
Go Rogue

Trial results for daraxonrasib, a daily KRAS inhibitor pill, have shown striking effects in patients with advanced pancreatic cancer that has spread.

Tumours stopped growing in 90% of the 61 trial patients, shrank or disappeared in just over 60%, and became undetectable on scans in about 8%, one in 12.

A year after starting treatment, 76.6% of patients were alive, well above the share who survive a year on chemotherapy alone.

Daraxonrasib works by locking on to and shutting off KRAS mutations found in most pancreatic cancers, and could potentially treat other cancers with similar mutations.

Doctors caution the pill is not yet a cure and that longer trials are needed, including before it can be assessed for NHS use.

Dr Wungki Park of Memorial Sloan Kettering Cancer Center presented the findings at a cancer symposium in Barcelona.

  1. Early trial results showed that more than three quarters of patients who took daraxonrasib survived past 12 months, compared with 25% of patients on standard chemotherapy.

  2. Dr Sam Godfrey of Cancer Research UK said the trial results were incredibly exciting, that daraxonrasib had found 'a way of drugging the undruggable', and that the world is finally seeing long overdue progress in pancreatic cancer.

    Prof Elena Garralda, chair of the European cancer conference EORTC, said the results are exciting because the combined treatment could potentially significantly improve patients' overall survival and the time before tumours start to grow again.

  3. Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the daraxonrasib findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

    In the trial of 61 patients with recently diagnosed advanced pancreatic cancer that had spread, tumours stopped growing in 90%, shrank or disappeared in just over 60%, and became undetectable on CT scans in about 8%, one in 12.

    A year after starting treatment, 76.6% of the trial patients were alive, compared with the usual 40-45% of patients given chemotherapy alone.

    Patients in the daraxonrasib trial were followed for a year and a half on average, and some did not see their cancer return during that period.

    Doctors said daraxonrasib cannot yet be considered a cure and that they do not know how long it can keep the disease at bay.

    Daraxonrasib is a KRAS inhibitor that works by locking on to and shutting off mutations found in most pancreatic cancers, mutations that drive tumour growth.

    It is hoped the daraxonrasib treatment could work for dozens of other cancers that carry similar mutations.

    Cancer Research UK's chief executive, Michelle Mitchell, called the daraxonrasib results 'the biggest leap forward we've seen in decades for pancreatic cancer patients' and said more trials are needed before the drug can be assessed for use on the NHS.

    Dr Wungki Park said he had never seen so many tumours disappear in patients whose cancer had spread, and called the disease vanishing from a CT scan 'the closest to cure' and 'incredible'.

  4. Dr Sam Godfrey of Cancer Research UK called the pancreatic cancer pill treatment 'a big science win'.

  5. A new study found that daraxonrasib combined with chemotherapy shrank tumours in more than 60% of the 60 patients tested and made cancer undetectable in 8% of them.

    In the study, tumours stopped growing in over 90% of patients, with the effect lasting more than a year on average before the cancer returned or began growing again.

    Dr Wungki Park said, 'We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease,' and called the finding a potentially transformative advance in first-line treatment for metastatic pancreatic cancer.

Sign in with subscription

Free during the beta.

Clear all notifications?

Your bells stay on. Only this list empties.